Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apyx Medical's change in receivables for the quarter that ended in Jun. 2026 was €-0.82 Mil. It means Apyx Medical's Accounts Receivable
increased by €0.82 Mil
from Mar. 2026 to Jun. 2026 .
Apyx Medical's change in receivables for the fiscal year that ended in Dec. 2025 was €-1.13 Mil. It means Apyx Medical's Accounts Receivable
increased by €1.13 Mil
from Dec. 2024 to Dec. 2025 .
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Apyx Medical's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 89.48.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Apyx Medical's liquidation value for the
three
months ended in Jun. 2026 was €-5.89 Mil.
Apyx Medical (FRA:BOV) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Apyx Medical's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apyx Medical Change In Receivables Related Terms
Apyx Medical Change In Receivables Historical Data
* Premium members only.
The historical data trend for Apyx Medical's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of €-2.29 Mil mean?
Apyx Medical (FRA:BOV) has a Change In Receivables of €-2.29 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Apyx Medical and its competitors.
Is Apyx Medical's Change In Receivables too high?
Apyx Medical's current Change In Receivables is €-2.29 Mil. Overall, Apyx Medical has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Apyx Medical's Change In Receivables compare to INGN and QSI?
Apyx Medical's Change In Receivables of €-2.29 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Apyx Medical and its competitors. Apyx Medical's current Change In Receivables is €-2.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apyx Medical stock overvalued right now?
Apyx Medical (FRA:BOV) has a current Change In Receivables of €-2.29 Mil. The stock's GF Value™ is €1.85, compared to a current price of €2.56 — trading 38.4% above its estimated fair value. The current Change In Receivables is €-2.29 Mil. Apyx Medical's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Apyx Medical (FRA:BOV), the current Change In Receivables is €-2.29 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apyx Medical (FRA:BOV) Overvalued in 2026?
Based on GuruFocus' analysis, Apyx Medical stock appears to be overvalued.
The current stock price of €2.56 is trading 38.4% above its estimated GF Value™ of €1.85.
Key valuation signals for FRA:BOV:
Change In Receivables: €-2.29 Mil
GF Value™: €1.85 vs. price of €2.56 (38.4% above fair value)
No single metric tells the full story. See the FRA:BOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
72GF Score
Get the complete analysis for FRA:BOV
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BOV has been successfully added to your 
